Entropy Neurodynamics

Entropy Neurodynamics Cash Flow per Share

Operating Cash Flow per Share of Entropy Neurodynamics (ENP.AX) as of Nov 22, 2026.

Cash Flow per Share

-0.00AUD

YoY

-60.89%

Last updated:

Operating Cash Flow per Share of Entropy Neurodynamics is 2026 -0.00 AUD. Operating Cash Flow per Share of Entropy Neurodynamics was 2025 -0.01 AUD. It decreases by -60.89% higher compared to the previous year.

The Entropy Neurodynamics Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2019
-0.05 AUD
Jan 1, 2020
-0.13 AUD
Jan 1, 2021
-0.11 AUD
Jan 1, 2022
-0.12 AUD
Jan 1, 2023
-0.02 AUD
Jan 1, 2024
-0.01 AUD
Jan 1, 2025
-0.01 AUD
Jan 1, 2026
-0.00 AUD
The Entropy Neurodynamics Cash Flow per Share history
YEARCash Flow per ShareYoY
-0.00AUD-60.89%
-0.01AUD-1.41%
-0.01AUD-77.07%
-0.02AUD-81.05%
-0.12AUD+8.93%
-0.11AUD-13.35%
-0.13AUD+145.35%
-0.05AUD+1,104.72%
-0.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics